Ad hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences increases the annual guidance for 2025…
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of…
H1 total sales growth of 11.4% at CER1, or 9.7% as reported, driven by the three therapeutic areas: 95.7% in…
BENGALURU, India, June 3, 2025 /PRNewswire/ -- Sagility India Limited (NSE: SAGILITY) (BSE: 544282), a leading global provider of technology-led…